GHRP-6 vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
GHRP-6GLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- GHRP-6 is the original synthetic GH-releasing peptide and a potent ghrelin receptor agonist. It produces strong GH pulses but is notorious for a significant hunger surge 30–45 minutes post-injection. This hunger side effect makes it less preferred than Ipamorelin or GHRP-2 for most protocols but can be useful in patients with appetite deficiency.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- 15–60 minutes
- ~5 days
- Admin Route
- SubQ, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- 2–3 times daily
- Once weekly, subcutaneous
- Key Benefits
- Strong GH stimulation
- Elevated IGF-1
- Muscle growth and recovery support
- Potential anti-inflammatory effects at GI level
- Useful for patients with appetite deficiency or cachexia
- Enhanced recovery from training
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Intense hunger surge (30–45 min post-injection)
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —